PURPOSE: To prospectively analyze patterns of failure in patients with head-and-neck squamous cell carcinoma treated withdefinitive high-precision radiotherapy with a focus on location of failure relative to target volume coverage. METHODS AND MATERIALS: Sixty patients treated withthree-dimensional conformal radiotherapy or intensity-modulated radiation therapy were included. Locoregional failure volume was defined on the planning data set at relapse, and dose received was analyzed by use of dose-volume histograms. RESULTS:Thirteen patients were deemed to have had locoregional failures, of which two did not have any viable tumor on salvage neck dissection, leaving eleven patients with proven persistent or recurrent locoregional disease. Of these, 9 patients had in-field failure, 1 marginal failure, and 1 both in-field and marginal failures. Overall, only 2 of 11 patients (18%) with relapse had any marginal failure. Of the 20 sites of locoregional failure, 15 (75%) were in-field and 5 (25%) marginal. Distant metastases were detected in 3 patients, whereas a second new primary developed in 3 others. With a median follow-up of 26 months (interquartile range, 18-31 months) for surviving patients, the 3-year local control, locoregional control, disease-free survival, and overall survival rates were 75.3%, 74%, 67.2%, and 60.5%, respectively. CONCLUSIONS:Locoregional relapse remains the predominant pattern of failure in head-and-neck squamous cell carcinoma treated with high-precision definitive radiotherapy with the majority of failures occurring "in-field" within the high-dose volume. Marginal failures can occur, particularly in the vicinity of the spared parotid gland. The therapeutic index of high-precision conformal radiotherapy is largely dependent on adequate selection and delineation of target volumes and organs at risk.
RCT Entities:
PURPOSE: To prospectively analyze patterns of failure in patients with head-and-neck squamous cell carcinoma treated with definitive high-precision radiotherapy with a focus on location of failure relative to target volume coverage. METHODS AND MATERIALS: Sixty patients treated with three-dimensional conformal radiotherapy or intensity-modulated radiation therapy were included. Locoregional failure volume was defined on the planning data set at relapse, and dose received was analyzed by use of dose-volume histograms. RESULTS: Thirteen patients were deemed to have had locoregional failures, of which two did not have any viable tumor on salvage neck dissection, leaving eleven patients with proven persistent or recurrent locoregional disease. Of these, 9 patients had in-field failure, 1 marginal failure, and 1 both in-field and marginal failures. Overall, only 2 of 11 patients (18%) with relapse had any marginal failure. Of the 20 sites of locoregional failure, 15 (75%) were in-field and 5 (25%) marginal. Distant metastases were detected in 3 patients, whereas a second new primary developed in 3 others. With a median follow-up of 26 months (interquartile range, 18-31 months) for surviving patients, the 3-year local control, locoregional control, disease-free survival, and overall survival rates were 75.3%, 74%, 67.2%, and 60.5%, respectively. CONCLUSIONS: Locoregional relapse remains the predominant pattern of failure in head-and-neck squamous cell carcinoma treated with high-precision definitive radiotherapy with the majority of failures occurring "in-field" within the high-dose volume. Marginal failures can occur, particularly in the vicinity of the spared parotid gland. The therapeutic index of high-precision conformal radiotherapy is largely dependent on adequate selection and delineation of target volumes and organs at risk.
Authors: Dirk Van Gestel; Dirk Verellen; Lien Van De Voorde; Bie de Ost; Geert De Kerf; Olivier Vanderveken; Carl Van Laer; Danielle Van den Weyngaert; Jan B Vermorken; Vincent Gregoire Journal: Oncologist Date: 2013-05-30
Authors: Carlos E Cardenas; Abdallah S R Mohamed; Randa Tao; Andrew J R Wong; Mussadiq J Awan; Shirly Kuruvila; Michalis Aristophanous; G Brandon Gunn; Jack Phan; Beth M Beadle; Steven J Frank; Adam S Garden; William H Morrison; Clifton D Fuller; David I Rosenthal Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-19 Impact factor: 7.038
Authors: Pieter D de Veij Mestdagh; Eric van Werkhoven; Arash Navran; Jan Paul de Boer; Willem H Schreuder; Wouter V Vogel; Abrahim Al-Mamgani Journal: Clin Transl Radiat Oncol Date: 2019-04-19
Authors: P Balermpas; F Rödel; R Liberz; J Oppermann; J Wagenblast; S Ghanaati; P N Harter; M Mittelbronn; C Weiss; C Rödel; E Fokas Journal: Br J Cancer Date: 2014-08-05 Impact factor: 7.640